Veracyte Inc Shares Enter Oversold Territory
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy VCYT?
Source: NASDAQ.COM
- Oversold Signal: Veracyte Inc (Ticker: VCYT) hit an RSI of 29.0 on Wednesday, indicating an oversold condition, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: VCYT shares traded as low as $35.72, with the current price at $36.10, showing significant volatility compared to the 52-week low of $22.61 and high of $50.71, reflecting drastic market sentiment changes.
- Market Comparison: The low RSI of VCYT, compared to the S&P 500 ETF (SPY) RSI of 52.7, may attract bullish investors, indicating potential rebound opportunities that could influence future buying decisions.
- Investor Sentiment: Despite the current poor stock performance, the oversold signal may lead investors to reassess their strategies, especially amid increasing market volatility, potentially resulting in capital inflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCYT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 46.14 USD with a low forecast of 43.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 34.860
Low
43.00
Averages
46.14
High
50.00
Current: 34.860
Low
43.00
Averages
46.14
High
50.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veracyte to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Veracyte will announce its fourth quarter and full-year 2025 financial results after market close on February 25, 2026, reflecting the company's ongoing advancements in cancer diagnostics.
- Conference Call Details: Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss financial results and provide a business update, enhancing investor confidence in the company's future.
- Webcast Availability: The conference call will be streamed live on the company's website, with a replay available post-broadcast, ensuring that investors who cannot attend live can access critical information.
- Company Vision: Veracyte aims to transform cancer care through its high-performing diagnostics platform, leveraging extensive genomic and clinical data to solidify its leadership position in the global cancer diagnostics market.
See More
Veracyte Inc Shares Enter Oversold Territory
- Oversold Signal: Veracyte Inc (Ticker: VCYT) hit an RSI of 29.0 on Wednesday, indicating an oversold condition, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: VCYT shares traded as low as $35.72, with the current price at $36.10, showing significant volatility compared to the 52-week low of $22.61 and high of $50.71, reflecting drastic market sentiment changes.
- Market Comparison: The low RSI of VCYT, compared to the S&P 500 ETF (SPY) RSI of 52.7, may attract bullish investors, indicating potential rebound opportunities that could influence future buying decisions.
- Investor Sentiment: Despite the current poor stock performance, the oversold signal may lead investors to reassess their strategies, especially amid increasing market volatility, potentially resulting in capital inflows.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
- Earnings Forecast: Abbott anticipates Q4 2025 EPS of $1.50, reflecting an 11.9% year-over-year increase, indicating strong performance in its medical devices and nutrition segments.
- Diagnostics Growth: Despite revenue impacts from procurement programs in China, Abbott's diagnostics segment is expected to grow 0.8% year-over-year, demonstrating sustained global demand for routine diagnostic testing.
- Medical Device Sales Surge: The medical devices segment is projected to see a 12.5% year-over-year revenue increase, driven by diabetes care and cardiac rhythm management products, particularly following the launch and FDA approval of the Volt PFA catheter.
- Nutrition Innovation: Abbott's launch of low-sugar Glucerna and the Ensure Max Protein line is expected to contribute to a 3.3% year-over-year revenue growth in the nutrition segment, further solidifying its market position.
See More
Veracyte Projects 10%-13% Revenue Growth for 2026
- Financial Outlook: Veracyte anticipates total revenue for 2025 to reach between $570 million and $582 million, reflecting a 10% to 13% growth compared to 2024, which will further solidify its leadership in the cancer diagnostics market.
- Testing Revenue Growth: The company expects testing revenue to grow by 14% to 16% in 2026, amounting to between $559 million and $569 million, indicating strong demand and market potential for its core business.
- Adjusted EBITDA Margin: Veracyte projects an adjusted EBITDA margin exceeding 25% for 2025, demonstrating effective strategies in cost control and profitability enhancement.
- Product Launch Plans: The company plans to launch the Prosigna and TrueMRD platforms in 2026, which are expected to further expand patient reach and improve financial performance, showcasing its commitment to continuous innovation.
See More
Veracyte Reports $517M Full-Year Revenue, Up 16%
- Significant Revenue Growth: Veracyte anticipates full-year revenue between $515 million and $517 million for 2025, reflecting a 16% increase, which indicates sustained market demand in cancer diagnostics and enhances financial stability.
- Testing Revenue Surge: The company expects testing revenue to range from $491 million to $493 million, marking a growth of approximately 17% to 18%, showcasing its success in driving innovative testing products and solidifying its market position.
- Increased Testing Volume: Testing volume is projected to reach approximately 169,700 in 2025, a 19% increase, demonstrating effective strategies in expanding the customer base and enhancing service capabilities, thereby strengthening its competitive edge in a crowded market.
- Optimistic Future Outlook: Veracyte projects total revenue growth of 10% to 13% for 2026, reaching $570 million to $582 million, with testing revenue growth of 14% to 16%, indicating strong confidence in future product launches and market expansion, which could further drive shareholder value.
See More
Veracyte to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: Veracyte will announce its fourth quarter and full-year 2025 financial results after market close on February 25, 2026, reflecting the company's ongoing advancements in cancer diagnostics.
- Conference Call Details: Management will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss financial results and provide a business update, enhancing investor confidence in the company's future.
- Webcast Availability: The conference call will be streamed live on the company's website, with a replay available post-broadcast, ensuring that investors who cannot attend live can access critical information.
- Company Vision: Veracyte aims to transform cancer care through its high-performing diagnostics platform, leveraging extensive genomic and clinical data to solidify its leadership position in the global cancer diagnostics market.
See More
Veracyte Inc Shares Enter Oversold Territory
- Oversold Signal: Veracyte Inc (Ticker: VCYT) hit an RSI of 29.0 on Wednesday, indicating an oversold condition, suggesting that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Price Fluctuation: VCYT shares traded as low as $35.72, with the current price at $36.10, showing significant volatility compared to the 52-week low of $22.61 and high of $50.71, reflecting drastic market sentiment changes.
- Market Comparison: The low RSI of VCYT, compared to the S&P 500 ETF (SPY) RSI of 52.7, may attract bullish investors, indicating potential rebound opportunities that could influence future buying decisions.
- Investor Sentiment: Despite the current poor stock performance, the oversold signal may lead investors to reassess their strategies, especially amid increasing market volatility, potentially resulting in capital inflows.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
- Earnings Forecast: Abbott anticipates Q4 2025 EPS of $1.50, reflecting an 11.9% year-over-year increase, indicating strong performance in its medical devices and nutrition segments.
- Diagnostics Growth: Despite revenue impacts from procurement programs in China, Abbott's diagnostics segment is expected to grow 0.8% year-over-year, demonstrating sustained global demand for routine diagnostic testing.
- Medical Device Sales Surge: The medical devices segment is projected to see a 12.5% year-over-year revenue increase, driven by diabetes care and cardiac rhythm management products, particularly following the launch and FDA approval of the Volt PFA catheter.
- Nutrition Innovation: Abbott's launch of low-sugar Glucerna and the Ensure Max Protein line is expected to contribute to a 3.3% year-over-year revenue growth in the nutrition segment, further solidifying its market position.
See More
Veracyte Projects 10%-13% Revenue Growth for 2026
- Financial Outlook: Veracyte anticipates total revenue for 2025 to reach between $570 million and $582 million, reflecting a 10% to 13% growth compared to 2024, which will further solidify its leadership in the cancer diagnostics market.
- Testing Revenue Growth: The company expects testing revenue to grow by 14% to 16% in 2026, amounting to between $559 million and $569 million, indicating strong demand and market potential for its core business.
- Adjusted EBITDA Margin: Veracyte projects an adjusted EBITDA margin exceeding 25% for 2025, demonstrating effective strategies in cost control and profitability enhancement.
- Product Launch Plans: The company plans to launch the Prosigna and TrueMRD platforms in 2026, which are expected to further expand patient reach and improve financial performance, showcasing its commitment to continuous innovation.
See More
Veracyte Reports $517M Full-Year Revenue, Up 16%
- Significant Revenue Growth: Veracyte anticipates full-year revenue between $515 million and $517 million for 2025, reflecting a 16% increase, which indicates sustained market demand in cancer diagnostics and enhances financial stability.
- Testing Revenue Surge: The company expects testing revenue to range from $491 million to $493 million, marking a growth of approximately 17% to 18%, showcasing its success in driving innovative testing products and solidifying its market position.
- Increased Testing Volume: Testing volume is projected to reach approximately 169,700 in 2025, a 19% increase, demonstrating effective strategies in expanding the customer base and enhancing service capabilities, thereby strengthening its competitive edge in a crowded market.
- Optimistic Future Outlook: Veracyte projects total revenue growth of 10% to 13% for 2026, reaching $570 million to $582 million, with testing revenue growth of 14% to 16%, indicating strong confidence in future product launches and market expansion, which could further drive shareholder value.
See More
